Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MLYS 
Mineralys Therapeutics, Inc. Common Stock (MLYS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: MLYS (4-star) is a STRONG-BUY. BUY since 15 days. Simulated Profits (147.65%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $43.75
1 Year Target Price $43.75
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 67.49% | Avg. Invested days 28 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.81B USD | Price to earnings Ratio - | 1Y Target Price 43.75 |
Price to earnings Ratio - | 1Y Target Price 43.75 | ||
Volume (30-day avg) 8 | Beta -0.3 | 52 Weeks Range 8.24 - 39.20 | Updated Date 09/16/2025 |
52 Weeks Range 8.24 - 39.20 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.56 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -38.8% | Return on Equity (TTM) -63.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2552919610 | Price to Sales(TTM) - |
Enterprise Value 2552919610 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.41 | Shares Outstanding 77569696 | Shares Floating 46124211 |
Shares Outstanding 77569696 | Shares Floating 46124211 | ||
Percent Insiders 1.88 | Percent Institutions 96.8 |
Upturn AI SWOT
Mineralys Therapeutics, Inc. Common Stock
Company Overview
History and Background
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for hypertension and kidney diseases. It was founded in 2020 and went public in February 2023.
Core Business Areas
- Aldosterone Synthase Inhibitor Development: Mineralys is developing lorundrostat, a selective aldosterone synthase inhibitor, for the treatment of uncontrolled hypertension and other diseases related to aldosterone.
Leadership and Structure
The leadership team includes Jon Congleton (CEO) and Dr. David Rodman (Chief Medical Officer). The company operates with a focused team structure typical of a clinical-stage biotech.
Top Products and Market Share
Key Offerings
- Lorundrostat: Lorundrostat is Mineralys' lead product candidate, currently in Phase 2 clinical trials for uncontrolled hypertension. No market share data is available as the product is pre-commercial. Competitors developing similar treatments include Idorsia (ACT-709477) and other companies exploring aldosterone pathway modulation.
Market Dynamics
Industry Overview
The hypertension market is large and growing, with significant unmet needs for patients with uncontrolled hypertension despite existing treatments. Focus shifts towards specific targeted therapies.
Positioning
Mineralys is positioned as a company developing a novel, selective aldosterone synthase inhibitor. Its competitive advantage lies in the selectivity and potential efficacy of lorundrostat.
Total Addressable Market (TAM)
The TAM for hypertension treatments is estimated to be in the tens of billions of dollars. Mineralys is targeting a specific segment of the market - uncontrolled hypertension related to excess aldosterone - giving them a potentially significant market share if lorundrostat is approved.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action (aldosterone synthase inhibition)
- Focus on a specific unmet need (uncontrolled hypertension)
- Experienced leadership team
- Strong intellectual property position
Weaknesses
- Single product pipeline (lorundrostat)
- Clinical trial risk
- Pre-revenue stage
- Dependence on successful clinical trial outcomes
Opportunities
- Positive clinical trial results could lead to significant market value increase
- Potential for expansion into other aldosterone-related diseases
- Partnerships or acquisitions by larger pharmaceutical companies
- FDA approval for lorundrostat
Threats
- Clinical trial failures
- Competition from other hypertension treatments
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- IDRSF.PK
- MRK
- PFE
Competitive Landscape
Mineralys faces competition from companies with existing hypertension treatments and those developing novel therapies. Its advantage lies in its focus on aldosterone synthase inhibition. The market share for drugs that treat hypertension are spread between the three mentioned.
Growth Trajectory and Initiatives
Historical Growth: Since the company is new to the market, there is not enough historical data to asses growth trajectories.
Future Projections: Future growth depends on the successful development and commercialization of lorundrostat and the company's ability to secure funding.
Recent Initiatives: Recent initiatives include progressing lorundrostat through Phase 2 clinical trials.
Summary
Mineralys Therapeutics is a clinical-stage biopharmaceutical company with a promising lead candidate, lorundrostat, targeting uncontrolled hypertension. Its success hinges on positive clinical trial results and regulatory approval. The company faces risks associated with clinical development and competition in the hypertension market. However, successful development could lead to significant shareholder value. They need to ensure to manage cash burn effectively and continue to generate supportive clinical data.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Mineralys Therapeutics, Inc. website
- SEC filings
- Analyst reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mineralys Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Radnor, PA, United States | ||
IPO Launch date 2023-02-10 | President, CEO & Director Mr. Jon Congleton | ||
Sector Healthcare | Industry Biotechnology | Full time employees 51 | Website https://mineralystx.com |
Full time employees 51 | Website https://mineralystx.com | ||
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.